[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.75.176. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 114
Citations 0
Comment & Response
November 2015

Dosing Strategies of Bone-Targeting Agents—Reply

Author Affiliations
  • 1Division of Geriatric Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
JAMA Intern Med. 2015;175(11):1865-1866. doi:10.1001/jamainternmed.2015.4799

In Reply We appreciate the comments by Hutton et al regarding dosing frequency and the need to examine alternative dosing intervals. Given our study design, which used a single infusion, we do not know whether a different dosing interval would have been more or less effective or generated more or fewer adverse events in this cohort. However, because a single infusion of zoledronic acid has been shown to exert a positive effect on skeletal health for up to 5 years,1,2 we chose a 2-year dosing interval. We agree that additional research needs to be done on the dosing frequency, especially focusing on frail elderly patients for whom there are limited data on osteoporosis treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×